Clinical Presentation and Treatment of Childhood‐Onset Lupus Nephritis
Palavras-chave:
Child, Lupus Nephritis/drug therapy, Treatment OutcomeResumo
Introduction: Lupus nephritis (LN) in childhood usually presents after the age of 10 years and is more common in female children. Despite the availability of effective immunosuppressive therapies, treatment response in childhood‐onset LN remains suboptimal, with 50% to 78% patients in full remission at 24 months. Improvement in survivals have also plateaued in past decades, and up to 9% and 14% of children with childhood‐onset LN died or developed end‐stage kidney disease during the course of illness, respectively. In our study, we aim to evaluate clinical presentation of LN with childhood‐onset, the treatment regimen instituted and the transition to adulthood.Methods: Retrospective study of patients with LN followed by pediatric nephrology with subsequent transition to adult nephrology since 1995 to 2020.
Results: Fourteen patients (female:78.6%) with a median age of 26.3 ± 5.2 years (range 21‐44) were included. The median age of LN diagnosis was 13.6 years. The most common manifestation was proteinuria (71.4%). Of non‐renal manifestations, polyarthritis (100.0%) and rash (57.1%) were the most common. All patients underwent kidney biopsy with a majority of diffuse LN (class IV) (n=11, 78.6%). Induction therapy consisted of corticosteroids combined with other immunosuppressants, primarily cyclophosphamide (CYC) (n=5, 35.3%) or mycophenolate (MMF) (n=9, 64.7%). Maintenance therapy consisted of corticosteroids combined with primarily CYC (n=6, 42.9%) with posterior transition to MMF, or MMF (n=5, 35.7%) or azathioprine (n=3, 21.4%). A complete remission occurred in all patients. At the end of follow‐up, 11 patients (78.6%) were with MMF and oral corticosteroids and 3 patients were with oral corticosteroids. None of these patients developed end‐stage kidney disease or died.
Conclusion: The diagnosis of LN in pediatric age has its particularities and constitutes a challenge for the nephrology community. Biological therapy currently shows promise in improving the prognosis of these patients.
Downloads
Referências
Nelson MC, Chandrakasan S, Ponder L, Sanz I, Goldberg B, Ogbu EA, et al. Clinical Determinants of Childhood Onset Systemic Lupus Erythematosus among Early and Peri‐Adolescent Age Groups. Children. 2022;9:1865. doi: 10.3390/children9121865.
Oni L, Wright RD, Marks S, Beresford MW, Tullus K. Kidney outcomes for children with lupus nephritis. Pediatr Nephrol. 2021;36:1377‐85. doi: 10.1007/s00467‐020‐04686‐1.
Sinha R, Raut S. Pediatric lupus nephritis: Management update. World J Nephrol. 2014; 3: 16‐23
Tektonidou MG, Lewandowski LB, Hu J, Dasgupta A, Ward MM. Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta‐analysis of studies from 1950 to 2016. Ann Rheum Dis. 2017;76:2009‐16. doi: 10.1136/annrheumdis‐ ‐2017‐211663. Erratum in: Ann Rheum Dis. 2018;77:472.
Oni L, Beresford MW, Witte D, et al. Inter‐observer variability of the histological classification of lupus glomerulonephritis in children. Lupus. 2017; 26(11):1205–1211
Vachvanichsanong P, McNeil E. Pediatric lupus nephritis: more options, more chances? Lupus. 2013; 22: 545‐53
Chan EY, Yap DY, Wong WT, Wong WH, Wong SW, Lin KY, et al. Long‐Term Outcomes of Children and Adolescents With Biopsy‐Proven Childhood‐Onset Lupus Nephritis. Kidney Int Rep. 2022;8:141‐50. doi: 10.1016/j.ekir.2022.10.014.
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100:S1‐S276. doi: 10.1016/j.kint.2021.05.021.
Viteri B, Reid‐Adam J. Hematuria and Proteinuria in Children. Pediatr Rev. 2018; 39:573‐87.
Qiu S, Zhang H, Yu S, Yang Q, Zhang G, Yang H, et al. Clinical manifestations, prognosis, and treat‐to‐target assessment of pediatric lupus nephritis. Pediatr Nephrol. 2022;37:367‐76. doi: 10.1007/ s00467‐021‐05164‐y.
Vachvanichsanong P, McNeil E, Dissaneewate P. A 30‐year retrospective study on causes of death in childhood‐onset systemic lupus erythematosus in a tertiary care centre in Southern Thailand. Clin Exp Rheumatol. 2019; 37:879–84.
Tsang ASMW, Bultink IE, Heslinga M, et al. Both prolonged remission and lupus low disease activity state are associated with reduced damage accrual in systemic lupus erythematosus. Rheumatology. 2017;56:121‐8. doi: 10.1093/rheumatology/kew377.
Petri M, Magder LS. Comparison of remission and lupus low disease activity state in damage prevention in a united states systemic lupus erythematosus cohort. Arthritis Rheumatol. 2018;70:1790‐5. doi: 10.1002/art.40571.
Smith EM, Gorst SL, Al‐Abadi E, Hawley DP, Leone V, Pilkington C, et al. ‘It is good to have a target in mind’: qualitative views of patients and parents informing a treat to target clinical trial in juvenile‐onset systemic lupus erythematosus. Rheumatology. 2021;60:5630‐41. doi: 10.1093/rheumatology/keab173.
Cannon LA, Wenderfer SE, Lewandowski LB, Cooper JC, Goilav B, Knight AM, et al. Use of EuroLupus Cyclophosphamide Dosing for the Treatment of Lupus Nephritis in Childhood‐onset Systemic Lupus
Erythematosus in North America. J Rheumatol. 2022;49:607‐14. doi:
3899/jrheum.210428.
Chen HG, Chen JS, Chen YS, Yin CH, Chen HC, Chiou YH. Comparison
of mycophenolic acid with cyclophosphamide for the treatment of pediatric lupus nephritis: A retrospective study from a tertiary center hospital in Taiwan. J Microbiol Immunol Infect. 2023;56:1105‐13. doi: 10.1016/j.jmii.2023.08.003.
Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83:15‐29. doi: 10.1136/ard‐2023‐224762.
Chan EY, Yap DY, Colucci M, Ma AL, Parekh RS, Tullus K. Use of Rituximab in Childhood Idiopathic Nephrotic Syndrome. Clin J Am Soc Nephrol. 2023;18:533‐48. doi: 10.2215/CJN.08570722.
Chan EY, Wong SW, Lai FF, Ho TW, Tong PC, Lai WM, et al. Long‐term outcomes with rituximab as add‐on therapy in severe childhood‐onset lupus nephritis. Pediatr Nephrol. 2023;38:4001‐11. doi: 10.1007/s00467‐023‐06025‐6.
Brunner HI, Abud‐Mendoza C, Viola DO, Calvo Penades I, Levy D, Anton J, et al. Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo‐controlled trial. Ann Rheum Dis. 2020;79:1340‐8. doi: 10.1136/annrheumdis‐2020‐217101.
Stohl W, Kwok A. Belimumab for the treatment of pediatric patients with lupus nephritis. Expert Opin Biol Ther. 2023; 23:243‐51. doi: 10.1080/14712598.2023.2178297.
Pennesi M, Benvenuto S. Lupus nephritis in children: novel perspectives. Medicina. 2023; 59:1841. doi: 10.3390/medicina59101841.
Downloads
Publicado
Edição
Secção
Licença
Direitos de Autor (c) 2024 Rita M. Silva, Ana L. Correia , Maria G. Marques, Carolina Cordinhã, Catarina Romãozinho, Nuno A. Oliveira, Carmen do Carmo, Clara Gomes, Rui Alves (Author)
![Creative Commons License](http://i.creativecommons.org/l/by-nc/4.0/88x31.png)
Este trabalho encontra-se publicado com a Licença Internacional Creative Commons Atribuição-NãoComercial 4.0.